Regression of left ventricular hypertrophy in human hypertension with irbesartan
暂无分享,去创建一个
C. Held | L. Lind | T. Kahan | M. Osbakken | F. Nyström | J. Östergren | M. Edner | R. Müller-Brunotte | K. Malmqvist | A. Hägg | K. Öhman
[1] L. Mazzolai,et al. Comparative Safety and Tolerability of Angiotensin II Receptor Antagonists , 1999, Drug safety.
[2] B. Greenberg,et al. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. , 1999, Journal of cardiovascular pharmacology.
[3] Schmidt,et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension , 1998, Circulation.
[4] J. Díez,et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. , 1999, Journal of hypertension.
[5] T. Unger,et al. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[6] L. Mazzolai,et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. , 1998, Hypertension.
[7] R. Reeves,et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. , 1998, Hypertension.
[8] N. Ford,et al. Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy Subjects , 1998, Journal of clinical pharmacology.
[9] R. Schmieder,et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] GiuseppeSchillaci,et al. Prognostic Significance of Serial Changes in Left Ventricular Mass in Essential Hypertension , 1998 .
[11] T. Thomas,et al. Sodium‐lithium countertransport: physiology and function , 1998, Journal of hypertension.
[12] T. Kahan,et al. Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta-blockade , 1998 .
[13] M. Osbakken,et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. , 1998, Blood pressure.
[14] S. Julius,et al. SYMPATHETIC OVERACTIVITY AND CORONARY RISK IN HYPERTENSION , 1997 .
[15] B. Strauer,et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients , 1996, Journal of hypertension.
[16] A. Dominiczak,et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. , 1996, Circulation.
[17] D. Rizzoni,et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment , 1995, Journal of hypertension.
[18] L. Lind,et al. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome , 1995, Journal of hypertension.
[19] D. Levy,et al. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. , 1995, Journal of the American College of Cardiology.
[20] P. Blankestijn,et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. , 1995, Hypertension.
[21] J. Laragh,et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. , 1994, Journal of the American College of Cardiology.
[22] S. Julius. Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension. , 1993, Hypertension.
[23] J. Kaufman,et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. , 1993, The American journal of cardiology.
[24] K. Weber,et al. Cardioreparation and the concept of modulating cardiovascular structure and function. , 1993, Blood pressure.
[25] S. Daniels,et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. , 1992, Journal of the American College of Cardiology.
[26] K. Pennert,et al. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. , 1992, American journal of hypertension.
[27] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[28] J. Laragh,et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.
[29] L. Prisant,et al. Ambulatory blood pressure monitoring and echocardiographic left ventricular wall thickness and mass. , 1990, American journal of hypertension.
[30] G. Schillaci,et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. , 1990, Circulation.
[31] J. Laragh,et al. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. , 1990, Circulation.
[32] D E Manyari,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[33] N. Reichek,et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[34] M. Alam,et al. Atrioventricular valve plane displacement in healthy persons. An echocardiographic study. , 2009, Acta medica Scandinavica.
[35] R. Schmieder,et al. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? , 1988, The American journal of medicine.
[36] J. Laragh,et al. Left Ventricular Hypertrophy in Hypertension Prevalence and Relationship to Pathophysiologic Variables , 1987, Hypertension.
[37] J. Laragh,et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. , 1986, Annals of internal medicine.
[38] P. Kligfield,et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. , 1986, The American journal of cardiology.
[39] N. Reichek,et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.
[40] M. Hennersdorf,et al. The Heart in Hypertension , 1981, International Boehringer Mannheim Symposia.